Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant: the CEntralized Pan-Levant survey on tHE Undertreatment of hypercholeSterolemia (CEPHEUS) study. (October 2014)
- Record Type:
- Journal Article
- Title:
- Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant: the CEntralized Pan-Levant survey on tHE Undertreatment of hypercholeSterolemia (CEPHEUS) study. (October 2014)
- Main Title:
- Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant: the CEntralized Pan-Levant survey on tHE Undertreatment of hypercholeSterolemia (CEPHEUS) study
- Authors:
- Hammoudeh, Ayman J.
Echtay, Akram
Ghanem, Georges Y.
Haddad, Jihad
for the CEPHEUS-Levant survey investigators - Abstract:
- <abstract> <title>Abstract</title> <sec id="ss1"> <title>Background:</title> <p>Several studies that evaluated achieving lipid goals have demonstrated an undertreatment of dyslipidemia. We evaluated the use and efficacy of lipid-lowering agents (LLAs) in reducing low-density lipoprotein cholesterol (LDL-C) to recommended levels in the Levant region.</p> </sec> <sec id="ss2"> <title>Design and methods:</title> <p>A multi-center, cross-sectional survey enrolled 1002 dyslipidemic patients (August 2010 – January 2011) on LLAs for ≥3 months. Collection of data and blood samples was done over one visit. Physicians and patients filled out questionnaires pertaining to dyslipidemia diagnosis and treatment. LDL-C target levels were defined according to international guidelines.</p> </sec> <sec id="ss3"> <title>Results:</title> <p>The full analysis set included 992 patients. Mean age was 58.0 ± 11.6 years (41% women, 65.7% diabetics and 51.5% had history of coronary heart disease). LLAs were prescribed for primary prevention or secondary prevention or familial hypercholesterolemia in 45.8% and 52.8% and 1.4% of patients; respectively. Overall, 64.0% and 56.8% of the patients attained their LDL-C goal recommended by the NCEP ATP III and TJETF guidelines, respectively. According to the 2004 NCEP ATP III updated guidelines, about 24.8% of the very high risk group attained their LDL goal of ≤70 mg/dL. Smoking, diabetes, metabolic syndrome, history of cardiovascular disease, increased waist<abstract> <title>Abstract</title> <sec id="ss1"> <title>Background:</title> <p>Several studies that evaluated achieving lipid goals have demonstrated an undertreatment of dyslipidemia. We evaluated the use and efficacy of lipid-lowering agents (LLAs) in reducing low-density lipoprotein cholesterol (LDL-C) to recommended levels in the Levant region.</p> </sec> <sec id="ss2"> <title>Design and methods:</title> <p>A multi-center, cross-sectional survey enrolled 1002 dyslipidemic patients (August 2010 – January 2011) on LLAs for ≥3 months. Collection of data and blood samples was done over one visit. Physicians and patients filled out questionnaires pertaining to dyslipidemia diagnosis and treatment. LDL-C target levels were defined according to international guidelines.</p> </sec> <sec id="ss3"> <title>Results:</title> <p>The full analysis set included 992 patients. Mean age was 58.0 ± 11.6 years (41% women, 65.7% diabetics and 51.5% had history of coronary heart disease). LLAs were prescribed for primary prevention or secondary prevention or familial hypercholesterolemia in 45.8% and 52.8% and 1.4% of patients; respectively. Overall, 64.0% and 56.8% of the patients attained their LDL-C goal recommended by the NCEP ATP III and TJETF guidelines, respectively. According to the 2004 NCEP ATP III updated guidelines, about 24.8% of the very high risk group attained their LDL goal of ≤70 mg/dL. Smoking, diabetes, metabolic syndrome, history of cardiovascular disease, increased waist circumference, and elevated pre-treatment LDL-C level were all associated with not reaching LDL-C goals.</p> </sec> <sec id="ss4"> <title>Conclusions:</title> <p>Although the study cohort was a relatively high risk group and might not be representative of the general population, we found that about 60% of enrolled individuals achieved the LDL-C treatment goals and 24.8% of the very high risk group achieved the recommended LDL-C targets of ≤70 mg/dl; national strategies and aggressive awareness campaigns to effectively control lipid levels to recommended target levels, especially in the high risk groups, are urgently needed.</p> </sec> </abstract> … (more)
- Is Part Of:
- Current medical research and opinion. Volume 30:Number 10(2014:Oct.)
- Journal:
- Current medical research and opinion
- Issue:
- Volume 30:Number 10(2014:Oct.)
- Issue Display:
- Volume 30, Issue 10 (2014)
- Year:
- 2014
- Volume:
- 30
- Issue:
- 10
- Issue Sort Value:
- 2014-0030-0010-0000
- Page Start:
- 1957
- Page End:
- 1965
- Publication Date:
- 2014-10
- Subjects:
- Clinical medicine -- Periodicals
Therapeutics -- Periodicals
615.5 - Journal URLs:
- http://informahealthcare.com ↗
- DOI:
- 10.1185/03007995.2014.929095 ↗
- Languages:
- English
- ISSNs:
- 0300-7995
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3500.301000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3276.xml